Status: Not yet recruiting
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Participants needed: 177
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: 3D MedicinesUpdated: Mar 11, 2026
Eligibility criteria
Subject must sign the informed consent in person prior to beginning any screenin... [+9]
Known allergy to any of the active ingredients or excipients of the study drug,... [+16]